Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis

Zhang,Guoqiao; Zeng,Rong; Wang,Kai; A,Yinzhuoyang; Li,Linhai; Gong,Kunmei

doi:10.3892/ol.2019.9894

Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis

Authors:
- Guoqiao Zhang
- Rong Zeng
- Kai Wang
- Yinzhuoyang A
- Linhai Li
- Kunmei Gong
View Affiliations

Affiliations: Department of Oncology, The First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, P.R. China, Department of General Surgery, The First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, P.R. China
Published online on: January 4, 2019 https://doi.org/10.3892/ol.2019.9894
Pages: 2874-2880

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical efficacy and adverse reactions of pemetrexed combined with stereotactic gamma‑ray radiotherapy in the treatment of patients with lung adenocarcinoma brain metastasis in The First People's Hospital of Yunnan Province were evaluated. A total of 67 patients with lung adenocarcinoma brain metastasis in experimental group were treated with simple pemetrexed chemotherapy, and then with radiotherapy, followed by pemetrexed chemotherapy. Their treatment results were compared with those of 53 patients treated with simple gamma knife in control group. The results were analyzed by comparing the clinical efficacy, side reactions, serum level changes, and survival between the two groups. Among 67 patients in the experimental group, there were 16 cases of complete response (CR), 39 cases of partial response (PR), 7 cases of stable disease (SD) and 5 cases of progressive disease (PD), with an effective rate of 82.09% (55/67) and a tumor local control rate of 92.54% (62/67). Among 53 patients in the control group, there were 13 cases of CR, 20 cases of PR, 9 cases of SD and 11 cases of PD, with an effective rate of 62.26% (33/53) and a tumor local control rate of 79.25% (42/53). There were statistically significant differences in the effective rate and local control rate between the two groups (P<0.05). The 6‑, 12‑ and 24‑month survival rates in experimental group were higher than those in control group (P<0.05). The main adverse reactions after pemetrexed combined with radiotherapy were lower than those after simple radiotherapy (P<0.05). The expression levels of the tumor markers carcinoembryonic antigen (CEA) and cytokeratin fragment antigen 21‑1 (CYFRA21‑1) in the two groups of patients after treatment were lower than those before treatment (P<0.05). After treatment, the expression levels of serum CEA and CYFRA21‑1 in the experimental group were significantly lower than those in the control group (P<0.05). Pemetrexed combined with radiotherapy in the treatment of lung adenocarcinoma brain metastasis is more effective than simple radiotherapy, with lighter adverse reactions, worthy of clinical application and promotion.

View Figures

View References

1	Ning M, Chunhua M, Rong J, Yuan L, Jinduo L, Bin W and Liwei S: Diagnostic value of circulating tumor cells in cerebrospinal fluid. Open Med (Wars). 11:21–24. 2016.PubMed/NCBI
2	Kawabe T, Phi JH, Yamamoto M, Kim DG, Barfod BE and Urakawa Y: Treatment of brain metastasis from lung cancer. Prog Neurol Surg. 25:148–155. 2012. View Article : Google Scholar : PubMed/NCBI
3	Fidler IJ: The biology of brain metastasis: challenges for therapy. Cancer J. 21:284–293. 2015. View Article : Google Scholar : PubMed/NCBI
4	Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, et al: Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 34:123–129. 2016. View Article : Google Scholar : PubMed/NCBI
5	Jamal-Hanjani M and Spicer J: Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 18:938–944. 2012. View Article : Google Scholar : PubMed/NCBI
6	Liu WJ, Zeng XT, Qin HF, Gao HJ, Bi WJ and Liu XQ: Whole brain radiotherapy plus chemotherapy in the treatment of brain metastases from lung cancer: A meta-analysis of 19 randomized controlled trails. Asian Pac J Cancer Prev. 13:3253–3258. 2012. View Article : Google Scholar : PubMed/NCBI
7	Shi Y, Sun Y, Yu J, Ding C, Ma Z, Wang Z, Wang D, Wang Z, Wang M, Wang Y, et al: China experts consensus on the diagnosis and treatment of brain metastases of lung cancer (2017 version). Zhongguo Fei Ai Za Zhi. 20:1–13. 2017.(In Chinese). PubMed/NCBI
8	Rahn DA III, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM and Rich T: Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: Is there a difference in outcome between morning and afternoon treatment? Cancer. 117:414–420. 2011. View Article : Google Scholar : PubMed/NCBI
9	Peacock KH and Lesser GJ: Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol. 7:479–489. 2006. View Article : Google Scholar : PubMed/NCBI
10	Pan HC, Sheehan J, Stroila M, Steiner M and Steiner L: Gamma knife surgery for brain metastases from lung cancer. J Neurosurg. 102 Suppl:128–133. 2005. View Article : Google Scholar : PubMed/NCBI
11	Gerosa M, Nicolato A, Foroni R, Tomazzoli L and Bricolo A: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg. 102 Suppl:75–80. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg M and Scagliotti G: Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer. 13:24–30. 2012. View Article : Google Scholar : PubMed/NCBI
13	Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N and Hashimoto S: Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res. 32:4589–4596. 2012.PubMed/NCBI
14	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
15	Shi Y, Sun Y, Ding C, Wang Z, Wang C, Bai C, Bai C, Feng J, Liu X, Li F, et al: China experts consensus on icotinib for non-small cell lung cancer treatment (2016 version). Zhongguo Fei Ai Za Zhi. 19:489–494. 2016.(In Chinese). PubMed/NCBI
16	Wang XF, Wu YH, Wang MS and Wang YS: CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev. 15:363–368. 2014. View Article : Google Scholar : PubMed/NCBI
17	Nagashima T, Sakao Y, Mun M, Ishikawa Y, Nakagawa K, Masuda M and Okumura S: A clinicopathological study of resected small-sized squamous cell carcinomas of the peripheral lung: Prognostic significance of serum carcinoembryonic antigen levels. Ann Thorac Cardiovasc Surg. 19:351–357. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kulpa J, Wójcik E, Reinfuss M and Kołodziejski L: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 48:1931–1937. 2002.PubMed/NCBI
19	Sertić Milić H, Franjević A, Bubanović G, Marušić A, Nikolić I and Puljić I: Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream. Wien Klin Wochenschr. 127:465–471. 2015. View Article : Google Scholar : PubMed/NCBI
20	Szturmowicz M, Rudziński P, Kacprzak A, Langfort R, Bestry I, Broniarek-Samson B and Orłowski T: Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer. Pneumonol Alergol Pol. 82:422–429. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ramalingam S and Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 13 Suppl 1:5–13. 2008. View Article : Google Scholar : PubMed/NCBI
22	Muallaoglu S, Disel U, Mertsoylu H, Besen A, Karadeniz C, Taner Sumbul A, Abali H and Ozyilkan O: Acute infusion reactions to chemotherapeutic drugs: a single institute experience. J BUON. 18:261–267. 2013.PubMed/NCBI
23	Lindvall P, Bergström P, Löfroth PO, Henriksson R and Bergenheim AT: Hypofractionated conformal stereotactic radiotherapy alone or in combination with whole-brain radiotherapy in patients with cerebral metastases. Int J Radiat Oncol Biol Phys. 61:1460–1466. 2005. View Article : Google Scholar : PubMed/NCBI
24	Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C and Lee JS: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 77:556–560. 2012. View Article : Google Scholar : PubMed/NCBI
25	Al-Saleh K, Quinton C and Ellis PM: Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol. 19:e9–e15. 2012.PubMed/NCBI
26	Arrieta O, Villarreal-Garza C, Martínez-Barrera L, Morales M, Dorantes-Gallareta Y, Peña-Curiel O, Contreras-Reyes S, Macedo-Pérez EO and Alatorre-Alexander J: Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study. BMC Cancer. 13:2542013. View Article : Google Scholar : PubMed/NCBI
27	Hoang T, Xu R, Schiller JH, Bonomi P and Johnson DH: Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 23:175–183. 2005. View Article : Google Scholar : PubMed/NCBI
28	Muley T, Fetz TH, Dienemann H, Hoffmann H, Herth FJ, Meister M and Ebert W: Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer. 60:408–415. 2008. View Article : Google Scholar : PubMed/NCBI
29	Guo J, Yu J, Song X and Mi H: Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis. Open Med (Wars). 12:131–137. 2017.PubMed/NCBI
30	Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH and Goldman ID: The proton-coupled folate transporter: Impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol. 74:854–862. 2008. View Article : Google Scholar : PubMed/NCBI
31	Chattopadhyay S, Moran RG and Goldman ID: Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 6:404–417. 2007. View Article : Google Scholar : PubMed/NCBI
32	Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF and Ardizzoni A: Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer. 78:92–99. 2012. View Article : Google Scholar : PubMed/NCBI